Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07470853) titled 'A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors' on March 9.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Whitehawk Therapeutics, Inc.
Condition:
PROC
Platinum Resistant Ovarian Cancer
Endometrial Cancer
Intervention:
Drug: HWK-016, MUCIN-16-targeted ADC
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: March 15, 2026
Target Sample Size: 265
Countries of Recruitment:
United States
To know ...